2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage

Stay up to date with the latest developments in graft-versus-host disease with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.

CONGRESS | #Tandem2025
Viktor Arnhold, @MSKCancerCenter, discussed tissue tolerance in refractory GvHD. He suggested a steroid-sparing approach can be safe and efficacious in some patients, and reduce tissue-suppressive side effects. #GvHD pic.twitter.com/QSP8HPImkX

— GvHD Hub (@gvhd_hub) February 13, 2025

CONGRESS | #Tandem25
Kristina Maas-Bauer, Freiburg University, discussed ROCK 1/2 inhibition in GvHD. ROCK inhibition alters the cytokine profile and migration of DCs and macrophages. In addition, ROCK and JAK inhibition can be used together for a synergistic effect. #GvHD pic.twitter.com/LUsKkO3h6b

— GvHD Hub (@gvhd_hub) February 13, 2025

CONGRESS | #Tandem25
Carrie Kitko, @VUMChealth, discussed ruxolitinib, belumosudil, and axatilimab for fibrosis. All have shown to led to clinical improvement in fibrotic organs in GvHD, however complete response is rare. Future studies could focus on combining these agents for… pic.twitter.com/1ySoEh97kO

— GvHD Hub (@gvhd_hub) February 14, 2025

CONGRESS | #Tandem25
Joe Hsu, @StanfordMed discussed new treatments to target BOS in GvHD, including results from the STOP-BOS trial, and preclinical studies of Shc301. Although these treatments have shown promising results, further studies are needed. #GvHD… pic.twitter.com/aoqnQF2Mk0

— GvHD Hub (@gvhd_hub) February 14, 2025

CONGRESS | #Tandem25
Uday Popat, @MDAndersonNews presented results from a phase II study of itacitinib/PTCy/Tac for GvHD prophylaxis in a fractionated busulfan regimen. Low rates of aGvHD and cGvHD were observed with a 1 year GRFS of 69.7%. #GvHDhttps://t.co/7whprdsds2 pic.twitter.com/aReQkV0oQF

— GvHD Hub (@gvhd_hub) February 14, 2025

CONGRESS | #Tandem25
Rachel Salit, @fredhutch, presented results from a phase II study of Rux addition to standard GvHD prophylaxis in pts with MF. aGvHD and cGvHD was reduced in pts who received rux vs standard prophylaxis. NRM and survival were not affected. #GvHD… pic.twitter.com/hABH4C0N1L

— GvHD Hub (@gvhd_hub) February 14, 2025

CONGRESS | #Tandem25@AshleyHadjis, Hospital of the University of Pennsylvania, discussed associations between #GvHD biomarkers and frailty in older pts undergoing allo-HCT. Regardless of GvHD, higher ST2 levels at 6 months led to worse OS in older pts. https://t.co/7whprdsds2 pic.twitter.com/tNGahaW0PP

— GvHD Hub (@gvhd_hub) February 16, 2025

CONGRESS | #Tandem25 @MunaQayed, @EmoryUniversity discussed the impact of #GvHD on leukemia-free survival. In this study, GvHD did not reduce relapse risk in #ALL or #AML, and severe aGvHD led to inferior OS. https://t.co/7whprdsds2 pic.twitter.com/U1wdexxou8

— GvHD Hub (@gvhd_hub) February 16, 2025

CONGRESS | #Tandem25 @DrMonzrAlMalki @cityofhope presented results from the ACCESS study which assessed PTCy for #GvHD prophylaxis after MMUD PBSC. 1-year OS was 84%, 56% of pts experienced Grade 2-5 infection in the first 100 days post-transplant.https://t.co/7whprdsds2 pic.twitter.com/afCBNqClb3

— GvHD Hub (@gvhd_hub) February 16, 2025